传统的结/直肠癌化疗药物,作用选择性较低,副反应明显,疗效欠佳,患者病死率居高不下。寻找新型治疗药物,十分必要。在结/直肠癌发病机制的探索过程中,研究者发现:一些分子的变化影响着疾病进程,对病情起指示作用,有可能成为治疗靶点。围绕这些分子设计药物,制定治疗方案,有望提高疗效,改善病人生存质量,降低不良反应的发生。本文就结/直肠癌的部分潜在治疗靶点:EGFR,VEGF,HADC,COX-2,PPARγ及galectin-3做一综述。 Traditional knot / rectal cancer chemotherapeutic drugs, the role of selectivity is low, obvious side effects, poor efficacy, patients with high mortality. Looking for new treatment drugs, it is necessary. In the exploration of the pathogenesis of colorectal cancer, the researchers found that some molecular changes affect the course of the disease and are indicators of the disease and may be therapeutic targets. The design of drugs around these molecules, the development of treatment options, is expected to improve the curative effect, improve patient quality of life, reduce the incidence of adverse reactions. This review summarizes some of the potential therapeutic targets for node / rectal cancer: EGFR, VEGF, HADC, COX-2, PPARγ, and galectin-3.